High Growth Non-Invasive Cancer Test Technology: Guardant Health Vs. Exact Sciences

During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for c.....»»

Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies fo.....»»

Shares of EXACT Sciences Corporation (NASDAQ: EXAS), which markets the non-invasive colon cancer screener Cologuard, enjoy a premium valuation and hold further upside potential, according to Goldman Sach.....»»

Novant Health recently implemented new robotics technology to improve diagnostics and treatment for lung cancer patients......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

A biotech unveils a new Covid-19 antibody test, while Thermo Fisher buys a cell sorting technology firm. Here's The Petri Dish, a roundup of Greater Boston life sciences and health care happenings......»»

Thanks to a competitor disclosing data showing its screening test isn't as efficient at detecting early-stage colon cancer, Exact Sciences Corp., the maker of the Cologuard stool-based colon cancer test, saw a leap in its stock price on Wednesday. The.....»»

One analyst sees FDA approval of its noninvasive colorectal cancer screening test tacking on another 30% to Exact Sciences stock......»»

U.S. stocks retreated from record highs on Monday, weighed by technology shares ahead of high profile earnings including that of Apple, which will test the impact of trade tensions on global growth, ahead of the Federal Reserve's policy-setting meeting......»»

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers......»»

Cancer diagnostics company Exact Sciences Corp said on Monday it will buy healthcare company Genomic Health Inc for about $2.8 billion to bolster its cancer testing business......»»

Cancer diagnostics company Exact Sciences Corp is in advanced negotiations to buy healthcare company Genomic Health Inc for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday......»»

Shareholders in the innovative colon cancer test specialist have enjoyed huge gains over the last few years......»»

Exact Sciences Corp. , maker of a colon cancer test, had shares surge 11% in extre.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Exact Sciences Corp., the maker of the Cologuard stool DNA-based colorectal cancer take-home test, saw a 78 percent increase in revenue for its recent second quarter when compared with the year-ago quarter, but still missed analysts' revenue projections......»»

Exact Sciences Corp. shares soared about 11% in premarket trade Wednesday, after the company said it will collaborate with Pfizer Inc. in co-promoting Cologuard, the first and only FDA-approved non-invasive stool DNA screening test fo.....»»

Global pharmaceutical company Pfizer Inc. has entered into a four-year agreement with Exact Sciences Corp. to co-promote and sell Cologuard, the noninvasive stool DNA-based colorectal cancer take-home test that was developed by Rochester, Minn.-bas.....»»

Kumar reiterates Overweight rating and $130 PT for Micron Technology, with promising insights into HBM market and commitment to innovation. Latest Rat.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»